Table 1 Overview of literature reported EBV+ BIA-DLBCL

Morgan S, et al. [11]

69

12

No

NA

Treatment for breast carcinoma (chemotherapy+RT)

CD45⁺, CD20⁺, PAX5⁺, CD79A⁺, CD30^-/+ (weak), MUM1⁺, BCL6⁺, CD10^-, CD138^-

CD45⁺,CD5^-, CD2^-, CD3^-, CD4^-, CD8^-, ALK^-, CD30^-/+ , Granzyme B^-, perforin^-

MYC⁺ (30%), CD138^-, Ki-67 proliferation index: 80%, HHV8^- , AE1/AE3^-

NA

IGH, IGK clonal gene rearrangement, no TCRb or g clonal rearrangement

T3N0M0 (BM aspirate+biopsy: lymphoma clear)

Capsulectomy

CR (Follow-up 24 months)

Morgan S, et al. [11]

53

9

No

FA-DLBCL

Unknown

CD20⁺, PAX5⁺, CD30⁺, BCL2⁺ (100%), MUM1⁺, BCL6^-, CD10^-, CD19⁺, CD79A⁺, OCT2^-, CD138^-

CD30⁺, CD5^-, CD3^-, ALK^-, CD2^-

MYC⁺(50-60%), CD68^-, HHV8^-, calretinin^-, EMA^-, CAM5.2^-, MIB-1 proliferation index > 90%

NA

FISH: MYC gene rearrangement without BCL2 gene rearrangement.

T2N0M0

Capsulectomy + 4 cycli R-CHOP

CR (Follow-up 36 months)

Mansy M., et al. [12]

46

5

No

FA-DLBCL

NA

CD30⁺, CD20⁺, PAX5⁺, BCL6⁺, MUM1⁺, CD10^-BCL2⁺

CD30⁺, ALK^-, CD2^-, CD3^-, ALK^-

EMA⁺, HHV8^-, Ki67 proliferation index > 90%

III

clonal rearrangement for the V-J(FR2) target,

polyclonal pattern in all IGK targets.

polyclonal pattern in TRG targets

(TRB not analyzed).

T3N0M0

Capsulectomy

CR (Follow-up 24 months)

Malata M. C., et al. [13]

51

21

No

FA-DLBCL

HIV

CD30⁺, CD45⁺, PAX5⁺, CD79A⁺, BCL2⁺, MUM1⁺, BCL6⁺, CD10^-, CD138^-

CD30⁺, CD45⁺, CD3^-, CD5^-, CD2^-, ALK^-

CD138^-, HHV8^-, MIB-1 proliferation index: 80%

NA

NA

T2/3N0M0

Small volume axillary nodes on CT

Capsulectomy

CR (Follow-up 24 months)

Khoo C., et al. [14]

70

9

No

FA-DLBCL

Unknown

CD30⁺, CD45⁺, CD79A⁺, CD20⁺, PAX5⁺, BCL6⁺, MUM1⁺, PD-L1⁺ (SP142 clone), CD10^-

CD45⁺, CD30⁺, CD3^-, CD2^-, CD4^-, CD5^-, CD7^-, CD8^-, TIA1^-, perforin^-, Granzyme B^-, ALK^-

CD68^-, AE1^-/AE3^-, Cam 5.2^-, EMA^-, HHV-8^-

NA

Monoclonal peak in IHC rearrangement 

T3N0M0

Capsulectomy

CR (Follow-up 12 months)

Mescam L., et al. [10]

72

NA

No

intermediate features between CI- and FA-DLBCL

Unknown

CD30⁺,CD45⁺, CD19⁺, CD20⁺, CD22⁺, CD79A⁺, PAX5⁺, MUM1⁺, CD138⁺, BCL2⁺

CD30⁺,CD45⁺, CD56^-

CD56^-, HHV8^-

Ki67 (100%)

III

Major monoclonal Ig

rearrangement and minor TCR rearrangement (1-2% T cells)

FISH: no rearrangement of BCL2, BCL6, MYC.

tNGS (30% tumor cells): damaging somatic mutations of IRF4 (p.L24F; VAF 10.4%),

T3N0M0

(normal PET scan)

Capsulectomy

CR (19 months after surgery).

Mescam L., et al. [10]

61

NA

No, invasive

intermediate features between CI- and FA-DLBCL

Unknown

CD30⁺, CD45⁺, CD79A⁺, MUM1⁺, CD10⁺, BCL6⁺, Kappa⁺, CD138⁺

CD45⁺, CD4⁺, CD30⁺, CD56⁺

EMA⁺, CD56⁺, CD138⁺, HHV8^-

Ki67 (100%)

III

Major monoclonal IG Rearrangement and minor TCR rearrangement (10% T-cells) FISH: IGH-MYC

translocation, no rearrangement of BCL2 or BCL6.

pT4

(normal PET scan)

Capsulectomy

CR (Follow-up 21 months)

Mescam L., et al. [10]

69

NA

No

intermediate features between CI- and FA-DLBCL

Unknown

CD30⁺, CD45⁺, CD19⁺, CD20⁺, CD22⁺, CD79A⁺, MUM1⁺, BCL6⁺

CD30⁺, CD45⁺, CD56^-

CD56^-, CD138^-

HHV8^-

Ki67 (80%)

III

Ig gene replacements and a small TCR,

FISH: no rearrangement of

BCL2, BCL6, MYC.

T3N0M0

(Normal PET scan)

Capsulectomy + 3X R-CHOP

CR (20 months follow-up)

Rodriguez-Pinilla S., et al. [9]

55

15

no

NA

NA

CD30⁺, CD20⁺, CD79A⁺, PAX5⁺, MUM1⁺

CD30⁺, CD3^-, TIA1^-, perforin^-, granzyme B^-

p53^-, MYC^-, HHV8^-

III

NA

T3N0M0

Capsulectomy

CR (Follow-up 7 months)

Rodriguez-Pinilla S., et al. [9]

59

10

no

NA

Unknown ***

CD30⁺, CD20⁺, CD79A⁺, PAX5⁺, MUM1⁺

CD3^-, TIA1^-, perforin^-, granzyme B^-, CD30⁺

p53^-, MYC^-, HHV8^-

II or III

(LMP1+)

NA

T3N0M0

Capsulectomy

CR (Follow-up 41 months)

Rodriguez-Pinilla S., et al. [9]

63

20

yes

NA

Unknown ***

CD30⁺, CD20⁺, CD79A⁺, PAX5^-, MUM1⁺

CD3⁺, TIA1⁺, perforin⁺, granzyme B⁺, CD30⁺

p53^-, MYC^-, HHV8^-

III

NA

pT4

Capsulectomy

CR (Follow-up 2 months)

Medeiros J., 2021 [8]

48

21

Yes, invasive

NA

Unknown

CD30⁺, CD45⁺, PAX5⁺, CD79A⁺, CD15⁺, MUM1⁺

CD30⁺, CD45⁺

/

II

NA

pT4

(left axillary mass)

Capsulectomy + 4 cycli of R-CHOP

CR + relapse**

(Follow-up 71 mo.)

Medeiros J., 2021 [8]*

47-71 (median: 65)

Median10 yrs (4-26)

No

NA

Unknown

CD30 6/7 (85%)

CD45 7/7 (100%)

CD20 7/7 (100%)

PAX5 6/6 (100%)

CD79A 7/7 (100%)

MUM1 7/7 (100%)

BCL6 1/5 (20%)

CD10 0/7 (0%)

CD138 0/5 (0%)

CD30 6/7 (85%)

CD45 7/7 (100%)

CD3 0/5 (0%)

CD4 0/2 (0%)

CD5 0/5 (0%)

CD8 0/2 (0%)

ALK 0/7 (0%)

Granzyme B 0/1 (0%)

TIA1 (0/1 (0%)

Myc 5/6 (83%)

Ki-67 proliferation median 80%

EMA 0/2 (0%)

HHV-8 0/7 (0%)

III

IGH 3/3 (100%)

pT2 7/7 (100%)

6/7 Capsulectomy

1/7 Capsulectomy + 3X R-CHOP

CR (Follow-up median: 8 (1-96) months)

Case 1

75

28

Yes

CI-DLBCL

Treatment for breast carcinoma (chemotherapy)

+ hypoglobulinemia

CD30⁺, CD20⁺, CD79A⁺, BOB1^-, PAX5⁺, OCT2⁺, CD15⁺, CD19^-,  MUM1⁺, CD10^-, BCL6⁺

CD30⁺, CD3^-, CD4^-, CD8^-

Ki67 (70-80%), BCL2⁺, C-MYC (30%), PD-L1⁺

III

FISH gain of region 9p24

pT4pR0

Capsulectomy

CR (after 6  months)

Case 2

45

8

No

FA-DLBCL

HIV

CD30⁺ , CD20⁺, PAX5⁺, OCT2⁺, BOB1⁺, CD79A⁺, CD10^-, CD15^-, BCL6⁺, MUM1⁺, GATA3⁺ 

CD30⁺, CD2^-, CD3^-, CD4^-, CD8^-, CD5^-, TIA1^-, Perforin^-, Granzyme B^-

C-MYC in ~75% of atypical cells, BCL2⁺, Ki67 (>95%), HHV8^-, PD-L1⁺

III

IgH polyclonal, IgKA monoclonal in polyclonal background, IgKB polyclonal

pT2N0M0

(Bone marrow lymphoma clear)

Capsulectomy

CR (Follow-up 12 mo)